Department of Physiological Sciences and University of Arizona, Tucson, Arizona.
Department of Health Sciences, University of Arizona, Tucson, Arizona.
Antioxid Redox Signal. 2019 Nov 10;31(14):1027-1052. doi: 10.1089/ars.2018.7701. Epub 2019 Jun 18.
Acute respiratory distress syndrome (ARDS) is a severe, highly heterogeneous critical illness with staggering mortality that is influenced by environmental factors, such as mechanical ventilation, and genetic factors. Significant unmet needs in ARDS are addressing the paucity of validated predictive biomarkers for ARDS risk and susceptibility that hamper the conduct of successful clinical trials in ARDS and the complete absence of novel disease-modifying therapeutic strategies. The current ARDS definition relies on clinical characteristics that fail to capture the diversity of disease pathology, severity, and mortality risk. We undertook a comprehensive survey of the available ARDS literature to identify genes and genetic variants (candidate gene and limited genome-wide association study approaches) implicated in susceptibility to developing ARDS in hopes of uncovering novel biomarkers for ARDS risk and mortality and potentially novel therapeutic targets in ARDS. We further attempted to address the well-known health disparities that exist in susceptibility to and mortality from ARDS. Bioinformatic analyses identified 201 ARDS candidate genes with pathway analysis indicating a strong predominance in key evolutionarily conserved inflammatory pathways, including reactive oxygen species, innate immunity-related inflammation, and endothelial vascular signaling pathways. Future studies employing a system biology approach that combines clinical characteristics, genomics, transcriptomics, and proteomics may allow for a better definition of biologically relevant pathways and genotype-phenotype connections and result in improved strategies for the sub-phenotyping of diverse ARDS patients molecular signatures. These efforts should facilitate the potential for successful clinical trials in ARDS and yield a better fundamental understanding of ARDS pathobiology.
急性呼吸窘迫综合征(ARDS)是一种严重、高度异质的危重病,死亡率极高,受环境因素(如机械通气)和遗传因素的影响。ARDS 存在着重大的未满足需求,包括缺乏经过验证的 ARDS 风险和易感性预测生物标志物,这阻碍了 ARDS 临床试验的成功开展,以及缺乏新的疾病修正治疗策略。目前的 ARDS 定义依赖于临床特征,无法捕捉疾病病理、严重程度和死亡率风险的多样性。我们对现有的 ARDS 文献进行了全面调查,以确定与 ARDS 易感性相关的基因和遗传变异(候选基因和有限的全基因组关联研究方法),希望发现 ARDS 风险和死亡率的新生物标志物,并可能为 ARDS 找到新的治疗靶点。我们还试图解决 ARDS 易感性和死亡率方面存在的众所周知的健康差异。生物信息学分析确定了 201 个 ARDS 候选基因,通路分析表明,关键的进化保守炎症通路,包括活性氧、固有免疫相关炎症和内皮血管信号通路,具有很强的优势。未来采用将临床特征、基因组学、转录组学和蛋白质组学相结合的系统生物学方法的研究,可能会更好地定义生物学上相关的通路和基因型-表型联系,并为不同 ARDS 患者的亚表型分子特征提供更好的治疗策略。这些努力应该有助于在 ARDS 中成功开展临床试验,并对 ARDS 病理生物学有更好的基本理解。